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451 East Health Science Drive, GBSF, Suite 6510, Davis, CA 95616, USAIn nearly every multifactorial human disease, there are three periods that characterize our understanding and deﬁnition.
First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period
as information is obtained that redeﬁnes and expands basic and clinical knowledge that lacks the ﬁnal and important area
of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vig-
orous deﬁnition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary
biliary cirrhosis (PBC). The term PBC was ﬁrst used nearly 60 years ago and for the ﬁrst 40 or so years, the primary
research eﬀorts were directed at clinical deﬁnitions and pathology. Subsequently, with the advent of molecular biology,
there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial
antibodies. These eﬀorts have greatly helped in our understanding of not only the eﬀector mechanisms of disease, but also
the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful trans-
lation for speciﬁc therapy.
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The history of our knowledge of primary biliary cir-
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cholangitis; TGF, transforming growth factor.natural history, genetics, and immunopathology. How-
ever, these areas have been progressing at a very diﬀer-
ent pace since the ﬁrst use of the term PBC almost 60
years ago [1] and the subsequent description of the ﬁrst
patient series [2]. Similar to all complex diseases recog-
nizing multiple pathogenetic factors, research in PBC
begun over 30 years ago with descriptive data. Further,
evidence in each of the four major ﬁelds in PBC research
has then witnessed rapid and slow progression rates dur-
ing the past decades. In this review article, we will criti-
cally review the available data by highlighting the ﬁrst
two phases to ultimately encourage vigorous eﬀorts
aimed at completing the remaining unﬁnished business
in PBC research and cure.2. The diagnosis of PBC
The history and developments in the diagnosis of
PBC well resemble the proposed two phases ofPublished by Elsevier B.V. All rights reserved.
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phase is represented by the earlier major discoveries,
i.e., the description of AMA speciﬁcity [3] and the estab-
lishment of solid diagnostic criteria. Nevertheless, fur-
ther studies in the ﬁeld have led to the progressive
reduction of the AMA-negative subgroup, yet it remains
to be determined whether this fraction of PBC cases rep-
resents a technical limitation of current methods or is
indeed a distinct subpopulation with diﬀerent serology.
Most of the epidemiologic data used to determine the
incidence and prevalence rates of PBC are descriptive
[4]. PBC is considered to be most prevalent in England,
Scandinavia and in northern areas of the United States,
although a factitious prevalence due to more exhaustive
epidemiological studies from these countries cannot be
excluded. Indeed, prevalence rates for PBC appear to
vary widely in diﬀerent geographical areas and have
been reported to be as high as 402/million in northern
US [5], thus making PBC a rare disease according to
the 2002 Rare Disease Act. PBC epidemiology is often
based on diﬀerent case-ﬁnding methods and data are
thus diﬃcult to compare, yet the concept of a PBC geo-
epidemiological pattern has been supported also by ane-
doctal reports of disease clustering [6,7]. Hence, there is
the need for rigorous population-based studies in diﬀer-
ent geographical areas that do not imply selection bias,
as in the case of blood donors [8], or solid case-ﬁnding
methods.
Similar to the majority of autoimmune diseases, PBC
manifests a striking predominance in the female sex. In
fact, women with PBC are found to outnumber men by
as much as 9:1, although such gender ratio varies widely
in diﬀerent epidemiological studies [4] with the largest
non population-based study thus far reporting a 8:1
ratio [9].
Currently, the diagnosis of PBC is based on the pres-
ence of two out of three internationally accepted criteria,
i.e., detectable serum AMA (titer P1:40), increased
enzymes indicating cholestasis (i.e. alkaline phospha-
tase) for longer than 6 months, and a compatible or
diagnostic liver histology [10]. The classiﬁcation pro-Table 1
The history of developments observed in PBC diagnosis are well
representative of the diﬀerent discovery paces with the early major
discoveries in PBC diagnosis and the slow progression of newer
techniques for AMA testing
Reference
Phase 1 Earlier
breakthrough
Proof of AMA speciﬁcity [94]
Established diagnostic criteria [95]
Phase 2 Minimizing
AMA-negative
Use of recombinant antigens [96]
Use of multiplex AMA tests [12]
Phase 3 What is next? 100% speciﬁc histology
100% sensitive AMA tests
PBC-diagnostic ANA
Putative developments for the expected upcoming phases are
suggested.poses that a ‘deﬁnite’ diagnosis occurs only when all
three criteria are encountered. We believe this is too nar-
row as patients lacking serum AMA appear to follow a
similar natural history when compared to their AMA-
positive counterparts [11]. Although the need for a liver
biopsy remains critical for disease staging, the issue of
whether a liver biopsy is needed upon presentation is
still debated. Currently, a liver biopsy should be per-
formed when only one of the other two diagnostic crite-
ria is met while its need should be carefully evaluated in
the presence of serum AMA positivity and a biochemi-
cal cholestatic pattern for over 6 months. However, it
remains to be determined whether liver histology should
be obtained in the presence of serum AMA without ele-
vated alkaline phosphatase.
The recent development in our laboratory of a sensi-
tive bead assay able to detect AMA in 20% of otherwise
AMA-negative sera [12] strengthens the hypothesis that
AMA-negative PBC cases are secondary to limits in the
current testing methods and do not represent an inde-
pendent clinical entity. On the other hand, speciﬁc pat-
terns of anti-nuclear antibodies (ANA) have proven to
be PBC-speciﬁc [13] and are helpful tools in the manage-
ment of patients with PBC, particularly when lacking
AMA. From this point of view, however, prospective
data on their diagnostic signiﬁcance and their prevalence
in AMA-negative cases are awaited. Another issue in the
diagnosis of PBC includes the consistent ﬁnding of ele-
vated serum IgM levels that do not correlate with
AMA titers or disease stage yet appear to decrease when
UDCA is used [14].
These observations on the PBC diagnostic process
leads to the important question of what type of patients
should be suspected of having PBC. This is not of sec-
ondary importance since an early diagnosis appears to
be crucial to the eﬃcacy of available medical treatment,
i.e., ursodeoxyhcolic acid (UDCA), which is virtually
absent in advanced stages. The diagnosis of PBC is com-
monly made in asymptomatic subjects in which routine
tests have demonstrated elevated alkaline phosphatase
levels and further analyses are consistent with earlier
stages. Our series of over 400 patients followed at the
San Paolo School of Medicine of the University of
Milan over the past 30 years reﬂects this observation.
The proportion of new PBC cases presenting to our
attention with jaundice decreased dramatically from
50% in the 1973–1979 period to less than 5% in the
1992–1997 years and is currently an exceptional event
in our practice with over 80% being diagnosed in the
absence of symptoms. Indeed, classically described
symptoms for PBC include fatigue and pruritus [10].
The former complaint is, in our experience, poorly spe-
ciﬁc and we are convinced that rigorous prevalence stud-
ies taking into account the pre-diagnosis status and the
use of well selected controls should be encouraged to
minimize spurious ﬁndings. Indeed, somehow conﬂict-
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of life impairment [17,18] but their comparisons remain
diﬃcult due to social diﬀerences and the use of various
questionnaires.
What should come next? The awaited third phase is
represented, in our opinion, by the overcoming of cur-
rent histological and serological limitations, possibly
through the use of non-invasive diagnostic tools and
the use of 100% sensitive AMA tests. Lastly, the diag-
nostic role of PBC-speciﬁc ANA has not been fully
developed [13] and may hold the key to autoantibody
markers to better deﬁne patients with PBC.3. The natural history and treatment options of PBC
Several open questions remain in the treatment and
natural history of PBC and represent the awaited third
phase in this research area (Table 2). Indeed, the disease
progression may vary widely and it is not uncommon in
clinical practice to observe patients remaining asymp-
tomatic for numerous years and decades and others pro-
gressing rapidly to liver failure and liver transplantation.
Earlier evidence of UDCA eﬃcacy and the use of the
Mayo score ﬁrst led to believe that the solution to
PBC prognosis and treatment was at hand, yet the fol-
lowing studies have progressed slowly, as well repre-
sented by the weak results obtained with UDCA-based
combination treatments. What causes PBC severity
and progression of the disease remains unknown,
although data seem to indicate that genetic factors other
than those inducing the disease might play a role [19].
Among non genetic factors, our group and others have
recently proposed, based on cross-sectional [20] and lon-
gitudinal [21,22] studies, that PBC-speciﬁc ANA are
associated with a more aggressive disease. This was of
particular interest in the comparison with established
prognostic scores such as the Mayo score [23]. This
score is the only validated and widely utilized [24] based
on clinical and biochemical variables as represented by
cholestasis and liver function, thus possibly being lessTable 2
PBC natural history and treatment remain an unﬁnished business
Reference
Phase 1 Earlier
breakthrough
UDCA eﬃcacy [28]
Mayo score validation [23]
Phase 2 Later
developments
UDCA combination therapies [97]
ANA prognostic signiﬁcance [22]
Phase 3 What is next? Deﬁnition of UDCA response
Genetic factors in
PBC progression
The rapid pace of earlier discoveries well represent phase 1 and was
followed by slower developments with combination treatments and the
prognostic signiﬁcance of ANA. Future developments in the third
phase are hypothesized.helpful in early stages when no hyperbilirubinemia is
observed [22]. When symptomless at diagnosis, PBC is
associated with 10-year survival rates similar to age-
and sex- matched healthy individuals while 67% of
pre-cirrhotic patients will develop liver cirrhosis over a
7-year observation period while 70% of asymptomatic
patients will develop symptoms. Based on these data,
it has been hypothesized that survival rates of asymp-
tomatic patients with PBC is shorter than the general
population if symptoms develop during follow-up [25]
and this may be secondary to non liver related deaths
[26].
UDCA mechanism of action in PBC remains
incompletely understood but it has been hypothesized
that it is based on several factors, including stimula-
tion of impaired secretion of the bile-acid pool, reduc-
tion in proinﬂammatory cytokines, eﬀects on
apoptosis and on vasoactive mediators [27–29]. Doses
ranging from 13 to 15 mg/kg of UDCA are currently
recommended and lead to optimum bile enrichment
while the use of doses as high as 30–40 mg/kg/day
as recommended in primary sclerosing cholangitis is
currently not supported in PBC. A meta-analysis dem-
onstrated that an increased survival is obtained only
when a dose >13 mg/kg is prescribed [30] despite the
fact that a complete biochemical response to UDCA
is achieved in approximately 40% of treated patients.
We note, however, that the deﬁnition of complete
UDCA response should be a priority for future
research. Indeed, a complete biochemical response to
UDCA as normalization of alkaline phosphatase lev-
els is suggested as a major determinant of UDCA
eﬀectiveness on disease progression [31]. Immunosup-
pressive and antiﬁbrotic drugs have been also used
in PBC with poor eﬃcacy [32]. The use of corticoste-
roids is encouraged in combination with UDCA when
an overlap with autoimmune hepatitis is present. New
monoclonal antibodies and hematopoietic stem cell
transplantation may be promising in PBC. Liver
transplantation is the optimal treatment for end-stage
PBC [33] despite common recurrence [34] inﬂuenced
by immunosuppressive regimens and the recipient sex
[35].4. The aetiology of PBC: genetics and environment
The current hypothesis on PBC onset states that the
disease results from an environmental insult intervening
on a genetically susceptible background. It is also clear
that genetic components of PBC development cannot
be related to a single gene mutation as the disease does
not manifest a complete concordance in monozygotic
twin sets [36]. Indeed, data on the genetics of PBC are
so far derived only from case-control studies [37] and
this approach is clearly limited by control matching
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data, PBC familial occurrence and twin concordance
well represent the ﬁrst (descriptive) phase of research
eﬀorts while the plethora or following association stud-
ies represent a slower progression rate (Table 3).
The concordance rates in monozygotic twins for late-
onset autoimmune diseases range are on average well
below 50%. We reported that concordance rates for
PBC are 63% in 8 monozygotic sets and null in dizygotic
twins [36]. It is of interest to note that in some cases the
natural history of PBC as well as the comorbidities vary
signiﬁcantly between concordant twins. The phenotypi-
cal discordance could be caused by epigenetic factors,
diﬀerences in exposure to environmental factors such
as infections or xenobiotics, as illustrated below, as well
as serendipity. Consistent with twin data, we note the
occurrence of multiple cases among family member
(i.e., ‘familial PBC’) with diﬀerent prevalence rates [38]
and the resulting risk for ﬁrst-degree relatives of PBC
cases to develop the disease [9] or to manifest serum
AMA positivity [39].
Signiﬁcant associations with speciﬁc major histocom-
patibility complex (MHC) alleles have been reported in
many autoimmune diseases [40] while data in PBC have
been conﬂicting. The example of the MHC class II
DRB8 positive association is paradigmatic in the fact
that this has been repeatedly suggested without achiev-
ing universal agreement. In our Milan case series, this
association was not conﬁrmed when smaller patient
and control series were used [41] while the study of the
largest population of patients and controls demon-
strated a signiﬁcant association with the DR8 allele
[42,43]. Other association studies have investigated the
importance of class III MHC and other candidate genes
in determining PBC onset but, once again, associationsTable 3
PBC genetic and environmental bases recognize three phases with an
earlier rapid development of descriptive data on familial PBC and twin
concordance subsequently followed by a slower phase with unconclusive
association studies while recapitulation of the role of sex chromosome,
xenobiotics, and bacteria is awaited
Reference
Phase 1 Earlier
breakthrough
Familial PBC [4]
Twin concordance [98]
Risk factors [9]
Phase 2 Later
developments
HLA/non-HLA associations [99]
X chromosome defects [100]
Bacterial candidates [101]
Xenobiotic reactivity [56]
Phase 3 What is next? Genome-wide association
studies
Spontaneous animal models
Epigenetic studies
Recapitulation of bacteria
and chemicals
Epigenetic studies may constitute the key to a awaited third phase.have proven to be weak or failed independent conﬁrma-
tion [44].
A susceptible genetic background is necessary, yet
not suﬃcient, to induce PBC. Among environmental
candidates, evidence has been obtained for bacteria
and xenobiotics. Of the bacterial strains suggested to
lead to PBC through molecular mimicry [45], most evi-
dence has been reported for Escherichia coli, based on
the reports of an increased prevalence of urinary tract
infections in patients with PBC [9]. Contrasting evidence
has been collected on the role of Chlamydia pneumoniae
[46,47] and Helicobacter pylori [48–50] in the pathogen-
esis of PBC while data on Lactobacillus delbruekii are
promising and await further conﬁrmation [51]. We have
recently provided serological data suggesting that a
ubiquitous xenobiotic-metabolizing Gram-negative bac-
terium, Novosphingobium aromaticivorans, is the best
candidate yet for the induction of PBC, as it elicits a spe-
ciﬁc antibody-reaction (estimated to be 100- to 1000-
fold higher than against E. coli) and its 16S rRNA spe-
ciﬁc sequences were detected in human fecal samples
[52]. Most recently, our group has contributed to deter-
mine that the infection by N. aromaticivorans induces
PBC-like autoantibodies, autoreactive T cells, and liver
lesions [53].
Xenobiotics are foreign compounds that may either
alter or complex to deﬁned self or non-self proteins,
inducing a change in the molecular structure of the
native protein suﬃcient to induce an immune response
leading to chronic autoimmunity. Speciﬁc organic struc-
tures attached to the mitochondrial antigens are recog-
nized by PBC sera with a higher aﬃnity than the
native forms of such antigens [54–56]. Further, an halo-
genated compound is capable to induce AMA produc-
tion [57] and PBC-like liver lesions [58] in animal
models.
One current hypothesis may conjugate the evidence
obtained for N. aromaticivorans and xenobiotics and,
if proven, may prompt a new research impulse. The
microorganism enters the human system through the
digestive mucosa and bacterial mimics containing lipoic
acid residues at this point might be modiﬁed by xenobi-
otics to form immunoreactive adducts which activate
local dendritic cells. Antigen presenting cells may in turn
activate autoreactive T and B cells that are directed to
the liver through the portal system. T cells participate
directly in the autoimmune injury and/or further recruit
autoreactive lymphocytes. B cells, on the other hand,
secrete AMA, particularly of the IgA type. AMA IgA
are then transported to the vascular side of the bile duct
cell where they react with the PDC-E2-like molecules
located on the luminal surface cell membrane and
induce apoptosis. The immune complexes of post-apop-
totic PDC-E2 and IgG-AMA and the direct cytopathic
eﬀects of autoreactive T cells (and possibly AMA) con-
tribute to the tissue injury observed in PBC.
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Since the determination of PBC autoantigens in 1987
[3] there has been an enormous number of experimental
studies on the major components of PBC autoimmunity.
With the exception of AMA and autoreactive T cells,
data on other cell populations are of uncertain signiﬁ-
cance in PBC pathogenesis (Table 4). First, it is well
established that AMA are directed against members of
the 2-oxoacid dehydrogenase complexes (2-OADC),
among which the major epitopes are within the lipoylat-
ed domains of the E2 subunit of the pyruvate dehydro-
genase complex (PDC-E2) [59]. The pathogenic role of
AMA remains debated since no clinical correlation can
be found and animal models developing serum AMA
do not consistently manifest PBC-like liver lesions. Sec-
ond, autoreactive CD4+ and CD8+ T cells can be
detected in PBC peripheral blood, regardless of the
AMA status, and the inﬁltration of autoreactive T cells
in the liver and periductular spaces is one of the most
prominent immune features [60]. Autoreactive T cells
of both subtypes recognize PDC-E2 sequences overlap-
ping with the AMA epitopes [61]. An increase in cyto-
toxic T cell precursors in the blood in the early stages
of the disease compared to the advanced ones and a
10-fold increase of speciﬁc liver CD8+ T cells compared
to peripheral blood have been demonstrated [62]. Third,
additional data on the immunobiology components of
PBC autoimmunity has been recently obtained in
CD4+CD25 high natural regulatory T cells which appear
to be numerically reduced in PBC [63]. What drives the
immune mediated response to a ubiquitous antigen to
damage a single cell type with such speciﬁcity remains
unknown. The identiﬁcation of speciﬁc characteristics
of BEC [64,65] such as the diﬀerential expression of cell
adhesion molecules, the response to cytokines and
growth factors and their potential ability to act as anti-
gen presenting cells, may explain the strict organ speci-
ﬁcity of the immune mediated injury in PBC [66]. PBC
bile duct cells manifest unique features during apoptosis
while co-culture experiments do not support a direct role
for these cells in determining their immune-mediatedTable 4
PBC immunobiology was characterized by earlier discoveries leading to the deﬁn
is well represented by the study of T regulatory cells, apoptosis in cholangiocy
Phase 1 Earlier breakthrough Cloning of AM
Deﬁnition of a
Phase 2 Later developments Deﬁnition of T
Bile duct cell a
Innate immune
Phase 3 What is next? Proof of apopt
Deﬁnition of li
Recapitulation
The integration of these lines of evidence is the major awaited developmentinjury [67]. Indeed, Odin and colleagues ﬁrst reported
that glutathionylation of the lysine lipoic acid moiety
of PDC-E2 is dramatically reduced via Bcl-2 by serum
AMA [68]. The enhanced glutathionylation, linked to
the evidence that PDC-E2 is released from apoptotic
BEC without caspase cleavage, appears fundamental
in the recognition of the mitochondrial epitope by the
immune system upon cell death. A possible unifying
hypothesis has been proposed by Allina and colleagues
who recently demonstrated that apoptotic cells are
phagocytosed by BECs and consequently are an exoge-
nous source of autoantigens in cholangiocytes [69], pos-
sibly through anti-CD16 [70]. As a result, the impact of
putative changes in apoptosis [71] and autophagy [72]
speciﬁc to BEC remains to be fully determined in
PBC. Fifth, the innate immune compartment has been
recently investigated in PBC with promising results.
PBC monocytes manifest an increased response to path-
ogen associated stimuli, as indicated by higher levels of
pro-inﬂammatory cytokines [73]. Further, the hyper-
IgM associated with PBC is secondary to an aberrant
innate immune response, potentially induced by stimula-
tion of toll like receptor 9 by bacterial CpG-B [74]. Sim-
ilarly, Chuang and colleagues reported a marked
increase in the frequency and absolute number of blood
and liver NK cells in PBC cases [75].
As summarized in Table 4, we currently have access
to a signiﬁcant amount of descriptive and partially
mechanistic information on the immune alterations
associated with PBC. One hypothesis for the selective
destruction of cholangiocytes is based on the aberrant
expression of PDC-E2 on the cell surface, possibly sec-
ondary to cell-speciﬁc overexpression or to abnormal
intracellular turnover. Although it cannot be ruled out
that observed reactivities are in fact due to immune
complexes, it remains possible that the molecules
expressed on the ductular surface may not be PDC-E2
itself, but PDC-E2 mimics. Interestingly, IgA from
patients with PBC colocalize with PDC-E2 (or
PDC-E2 mimic) on the apical membrane of PBC
cholangiocytes [76] and these data are consistent with
the epithelium-speciﬁc damage.ition of AMA autoantigens and autoreactive T cells while a second phase
tes, and innate immune changes
Reference
A autoantigens [3]
utoreactive T cells [61]
reg defects [102]
poptosis uniqueness [68]
changes in PBC [73,74]
osis involvement in autoantigen recognition
poic acid critical role
of all of the above in an animal model
in the third phase.
Fig. 1. The current working hypothesis of PBC development is illustrated. The primum movens of the proposed mechanisms is based on the peculiar
apoptotic features of biliary epithelial cells (BEC). Secondary to a reduced glutathiolation (I), apoptotic BEC release an intact PDC-E2 (II) which
also includes lipoic acid (III). Lipoic acid in turn becomes the ideal target for xenobiotic-induced modiﬁcations with 2-octynoic acid as the best
candidate (IV) and with N. aromaticivorans possibly inﬂuencing this pathway (V). The modiﬁed or substituted lipoic acid residue is then uptaken by
antigen presenting cells (VII) and is capable of breaking immune tolerance (VIII) in the presence of a permissive genetic background. Female
predominance of PBC may be explained by major sex chromosome defects such as X monosomy (IX) or by the increased exposure to speciﬁc
xenobiotics (X). Indeed, individual susceptibility may be based on on a direct putative impact of a speciﬁc set of genes on disease development or
progression (XI), as suggested by association studies, or by epigenetic changes of sex (XII) or somatic (XIII) chromosomes that remain to be
investigated. The ultimate result of a permissive genetic background and an undertermined environmental exposure is the development and
perpetuation of the PBC liver injury (XIV).
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research impetus
During the past 4 years, new intriguing scenarios
have been proposed with important implications for
PBC and the resulting working hypothesis on PBC aeti-
ology and pathogenesis is summarized in Fig. 1. These
include new evidence on sex chromosomes and novel
comprehensive animal models.
First, the female preponderance may hold an impor-
tant key to PBC aetiology. The hypotheses based on sex
hormone inﬂuence on lymphocytes at various stages in
life [77–79] or fetal microchimerism [80] are inconclu-
sive. X-linked genes determine gender-related character-
istics at diﬀerent levels while also regulating the immune
function, particularly to maintain tolerance. Major X
chromosome defects such as those leading to Turner’s
syndrome [81] or premature ovarian failure [82] are
commonly characterized by autoimmune comorbidities
(particularly thyroid disease) and, less frequently, chole-
stasis. Our group ﬁrst determined a signiﬁcantly higher
frequency of monosomy of the X chromosome in
peripheral leukocytes (particularly those of the adaptive
immune response, i.e., T and B cells) in women PBC [36]
compared to age-matched control women. Monosomy
frequency correlated with age in all three groups, as
expected [83] but monosomic cells were not microchi-
meric cells [84]. Importantly, women with two other
female-predominant and late-onset autoimmune dis-
eases with diﬀerent organ speciﬁcity, i.e., systemic scle-
rosis and autoimmune thyroiditis, also manifested the
same diﬀerence [85]. This was not recapitulated in
women with systemic lupus erithematosus which, how-
ever, were signiﬁcantly younger [86]. We further demon-
strated that the X loss in PBC aﬀected was not random
but aﬀected more frequently one parentally inherited
chromosome [87]. We submit that the sex chromosome
hypothesis is indeed fascinating [88] and encourage inde-
pendent researchers to recapitulate our data on other
patient series.
The second important development during the past
few years has been the appearance of three animal mod-
els that may contribute to elucidating the undoubtedly
multi-factorial causation and progression of PBC [89].
First, a genomic variant of the non obese diabetic
(NOD) mouse (NOD.c3c4) has been observed to mani-
fest autoimmune cholestasis with AMA and ANA posi-
tivities in 50%–60% and 80%–90%, respectively. Liver
histology demonstrated portal lymphocyte inﬁltration
with chronic non-suppurative cholangitis and PBC-like
granulomas [90]. Second, a dominant negative form of
transforming growth factor b (TGFb) receptor II
(dnTGFbRII) mouse develop serum AMA in 100% of
mice. The TGFb receptor II regulates lymphocyte acti-
vation and the appearance of PBC in this model suggests
a speciﬁc condition of T cells with impaired TGFb sig-naling in the presence or absence of B cells is involved
[91]. Third, the knockout of interleukin 2 receptor a
leads to a murine phenotype with 100% serum AMA
positivity, 80% serum ANA positivity, and portal lym-
phocyte inﬁltration and vanishing bile ducts [92]. This
model is of particular interest based on the report of
autoimmune cholangitis in a pediatric case of IL2Ra
deﬁciency [93].
There appears to be new excitement caused by these
most recent lines of evidence among researchers
involved in PBC aetiopathogenesis. Indeed, we are also
convinced that the appearance of novel laboratory tools
such as genome-wide multiplex analysis methods capa-
ble of providing high-throughput analyses of genetic
polymorphisms or microRNA will prompt research
eﬀorts to ﬁnally determine the genetic bases of PBC.
Nevertheless, only a multicenter study comprising a
large number of PBC cases and well-matched controls
recapitulating available evidence will provide enough
power to proceed to the next much needed phase in
the study of PBC.References
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